Strategy for Treatment of Nonerosive Reflux Disease in Asia

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2008 May 29

PMID 18506915

Citations 20

Authors

Toru Hiyama

Masaharu Yoshihara

Shinji Tanaka

Ken Haruma

Kazuaki Chayama

Affiliations

Soon will be listed here.

Abstract

The paper is to review the clinical and pathophysiologic differences between of nonerosive reflux disease (NERD) and reflux esophagitis (RE), and to propose a treatment strategy for NERD, especially for patients in Asia. A Medline search was performed regarding the clinical and pathophysiologic differences between NERD and RE, and treatment of NERD and RE. The characteristics of NERD patients in Asia are as follows: (1) high proportion of female patients, (2) low frequency of hiatal hernia, (3) high frequency of H pylori infection, (4) severe glandular atrophy of the gastric mucosa, and (5) frequent resistance to proton pump inhibitor (PPI) therapy. In Asian NERD patients, exposure of the esophagus to acid is not increased, and esophageal motility is normal. These characteristics are similar to those of patients in Western countries. Our recommended first-choice treatment is administration of PPI in combination with a prokinetic agent. However, at present, because there is limited evidence regarding effective treatments for NERD, it is best to try several different treatment strategies to find the best treatment for each patient.

Citing Articles

Randomized Controlled Trial Comparing the Efficacy of Sustained-Release Formula of Mosapride-Plus-Esomeprazole Combination Therapy to Esomeprazole Monotherapy in Patients with Gastroesophageal Reflux Disease.

Jeon H, Kim G, Lee M, Joo D, Lee B J Clin Med. 2022; 11(7).

PMID: 35407572 PMC: 8999938. DOI: 10.3390/jcm11071965.

Efficacy and Safety of Traditional Chinese Medicine on Nonerosive Reflux Disease: A Meta-Analysis of Randomized Controlled Trials.

Xiao J, Yang Y, Zhu Y, Qin Y, Li Y, Fu M Evid Based Complement Alternat Med. 2018; 2018:1505394.

PMID: 29977310 PMC: 5994284. DOI: 10.1155/2018/1505394.

Expression of Serum Exosomal and Esophageal MicroRNA in Rat Reflux Esophagitis.

Uemura R, Murakami Y, Hashimoto A, Sawada A, Otani K, Taira K Int J Mol Sci. 2017; 18(8).

PMID: 28757556 PMC: 5578003. DOI: 10.3390/ijms18081611.

Omeprazole-Domperidone Fixed Dose Combination vs Omeprazole Monotherapy: A Phase 4, Open-Label, Comparative, Parallel Randomized Controlled Study in Mild to Moderate Gastroesophageal Reflux Disease.

Marakhouski K, Karaseva G, Ulasivich D, Marakhouski Y Clin Med Insights Gastroenterol. 2017; 10:1179552217709456.

PMID: 28607547 PMC: 5457029. DOI: 10.1177/1179552217709456.

Rikkunshito prevents paclitaxel-induced peripheral neuropathy through the suppression of the nuclear factor kappa B (NFκB) phosphorylation in spinal cord of mice.

Kamei J, Hayashi S, Sakai A, Nakanishi Y, Kai M, Ikegami M PLoS One. 2017; 12(2):e0171819.

PMID: 28182729 PMC: 5300261. DOI: 10.1371/journal.pone.0171819.

References

Barlow W, Orlando R . The pathogenesis of heartburn in nonerosive reflux disease: a unifying hypothesis. Gastroenterology. 2005; 128(3):771-8. DOI: 10.1053/j.gastro.2004.08.014. View

Moayyedi P, Talley N . Gastro-oesophageal reflux disease. Lancet. 2006; 367(9528):2086-100. DOI: 10.1016/S0140-6736(06)68932-0. View

Fass R . Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007; 41(2):131-7. DOI: 10.1097/01.mcg.0000225631.07039.6d. View

Prasad M, Rentz A, Revicki D . The impact of treatment for gastro-oesophageal reflux disease on health-related quality of life: a literature review. Pharmacoeconomics. 2003; 21(11):769-90. DOI: 10.2165/00019053-200321110-00002. View

Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M . Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials. J Gastroenterol Hepatol. 2007; 22(10):1566-70. DOI: 10.1111/j.1440-1746.2006.04723.x. View

Balaban D, Yamamoto Y, Liu J, Pehlivanov N, Wisniewski R, DeSilvey D . Sustained esophageal contraction: a marker of esophageal chest pain identified by intraluminal ultrasonography. Gastroenterology. 1998; 116(1):29-37. DOI: 10.1016/s0016-5085(99)70225-8. View

Watson R, Tham T, Johnston B, McDougall N . Double blind cross-over placebo controlled study of omeprazole in the treatment of patients with reflux symptoms and physiological levels of acid reflux--the "sensitive oesophagus". Gut. 1997; 40(5):587-90. PMC: 1027158. DOI: 10.1136/gut.40.5.587. View

Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T . Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006; 40(10):891-5. DOI: 10.1097/01.mcg.0000225673.76475.9d. View

Ruth M, Finizia C, Cange L, Lundell L . The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003; 15(10):1115-21. DOI: 10.1097/00042737-200310000-00009. View

10.

Kinoshita Y, Kobayashi T, Kato M, Asahina K, Haruma K, Shimatani T . The pharmacodynamic effect of omeprazole 10 mg and 20 mg once daily in patients with nonerosive reflux disease in Japan. J Gastroenterol. 2006; 41(6):554-61. DOI: 10.1007/s00535-006-1804-3. View

11.

Rodriguez-Stanley S, Robinson M, Earnest D, Greenwood-Van Meerveld B, Miner Jr P . Esophageal hypersensitivity may be a major cause of heartburn. Am J Gastroenterol. 1999; 94(3):628-31. DOI: 10.1111/j.1572-0241.1999.00925.x. View

12.

Vakil N, van Zanten S, Kahrilas P, Dent J, Jones R . The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101(8):1900-20. DOI: 10.1111/j.1572-0241.2006.00630.x. View

13.

van Pinxteren B, Numans M, Bonis P, Lau J . Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2006; (3):CD002095. DOI: 10.1002/14651858.CD002095.pub3. View

14.

Kuster E, Ros E, Pujol A, Bordas J, Grande L, Pera C . Predictive factors of the long term outcome in gastro-oesophageal reflux disease: six year follow up of 107 patients. Gut. 1994; 35(1):8-14. PMC: 1374623. DOI: 10.1136/gut.35.1.8. View

15.

Miwa H, Sasaki M, Furuta T, Koike T, Habu Y, Ito M . Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan. Aliment Pharmacol Ther. 2007; 26(1):69-77. DOI: 10.1111/j.1365-2036.2007.03350.x. View

16.

Kawahara H, Kubota A, Hasegawa T, Okuyama H, Ueno T, Ida S . Effects of rikkunshito on the clinical symptoms and esophageal acid exposure in children with symptomatic gastroesophageal reflux. Pediatr Surg Int. 2007; 23(10):1001-5. DOI: 10.1007/s00383-007-1986-7. View

17.

Graham D, Patterson D . Double-blind comparison of liquid antacid and placebo in the treatment of symptomatic reflux esophagitis. Dig Dis Sci. 1983; 28(6):559-63. DOI: 10.1007/BF01308159. View

18.

Ofman J . The economic and quality-of-life impact of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003; 98(3 Suppl):S8-S14. DOI: 10.1016/s0002-9270(03)00010-8. View

19.

Metz D, Inadomi J, Howden C, Veldhuyzen van Zanten S, Bytzer P . On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol. 2006; 102(3):642-53. DOI: 10.1111/j.1572-0241.2006.00998.x. View

20.

Lundell L, Dent J, Bennett J, Blum A, Armstrong D, Galmiche J . Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45(2):172-80. PMC: 1727604. DOI: 10.1136/gut.45.2.172. View